

MOST IMPORTANT
Through UMS/E-office

No.F.6-7/2026-MD (M-136)
Government of Pakistan
Ministry of National Health Services, Regulations & Coordination
Drug Regulatory Authority of Pakistan

Islamabad, the 9th July, 2026

Subject: MANDATORY TRANSITION FROM CONVENTIONAL TO SAFETY-ENGINEERED REUSE-PREVENTION (RUP) SYRINGES AND RESTRICTIONS ON MANUFACTURE/ IMPORT/ SALE OF CONVENTIONAL SYRINGES

This is in supersession of this office letter No.F.6-7/2026-MD (M-135) dated 1st July, 2026 on the subject cited above.


2. The Drug Regulatory Authority of Pakistan (DRAP), in exercise of its statutory power and mandate provided under the DRAP Act, 2012, strives to safeguard public health by ensuring that Therapeutic goods conform to international standards of quality, safety and performance. Pursuant to the directives of the Prime Minister's Office, a taskforce was constituted by the Ministry of National Health Services, Regulations and Coordination (NHSR&C) on 5th May, 2026, to investigate the reported surge of HIV cases associated with unsafe medical practices, particularly the alleged reuse of contaminated syringes and deficiencies in infection prevention and control mechanisms.

3. In accordance with the subsequent discussion during the meeting held in the Prime Minister's Office on 03-07-2026, the Medical Device Board, DRAP in its 136th meeting held on 9th July, 2026 considered the subject matter and decided as under: -

- i. There shall be complete restriction on manufacturing, import and sale of conventional disposable syringes of 10cc and below (except insulin syringes) with effect from 1st January, 2027.
- ii. All registered conventional disposable syringes of 10cc and below (except insulin syringes) shall transit to safety-engineered reuse-prevention (RUP) syringes equipped with validated auto-destructible, retractable, or auto-lock technologies before 31st December, 2026 after mandatory regulatory approval from Drug Regulatory Authority of Pakistan.



4. You are therefore directed to comply with the aforesaid directives/decisions in true letter and spirit.


(AYYAZ AHMAD)

Secretary Medical Devices Board

Distribution:

1. All concerned manufacturers and importers (list attached)

Copy for information & further necessary action, if any, to:

1. Director MD&MC, DRAP, Islamabad.
2. Director QA<, DRAP Islamabad.
3. Director MIS, DRAP, Islamabad with request to upload on DRAP's website.
4. Director to Secretary, Ministry of NHS, R&C, Islamabad.
5. Additional Director E&M/ Field office In-charge, DRAP Regional Offices Lahore, Karachi, Peshawar, Quetta, Islamabad.
6. DD to CEO, DRAP, Islamabad.
7. Meeting file/Office Copy.